- Home
- DMF vs PROK Comparison
DMF vs PROK Comparison
Compare DMF & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMF
- PROK
- Stock Information
- Founded
- DMF 1988
- PROK 2015
- Country
- DMF United States
- PROK United States
- Employees
- DMF N/A
- PROK N/A
- Industry
- DMF Finance/Investors Services
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DMF Finance
- PROK Health Care
- Exchange
- DMF Nasdaq
- PROK Nasdaq
- Market Cap
- DMF 152.2M
- PROK 126.8M
- IPO Year
- DMF N/A
- PROK N/A
- Fundamental
- Price
- DMF $7.25
- PROK $0.71
- Analyst Decision
- DMF
- PROK Buy
- Analyst Count
- DMF 0
- PROK 4
- Target Price
- DMF N/A
- PROK $5.00
- AVG Volume (30 Days)
- DMF 60.7K
- PROK 410.9K
- Earning Date
- DMF 01-01-0001
- PROK 05-09-2025
- Dividend Yield
- DMF 2.66%
- PROK N/A
- EPS Growth
- DMF N/A
- PROK N/A
- EPS
- DMF 0.15
- PROK N/A
- Revenue
- DMF N/A
- PROK $76,000.00
- Revenue This Year
- DMF N/A
- PROK N/A
- Revenue Next Year
- DMF N/A
- PROK N/A
- P/E Ratio
- DMF $45.13
- PROK N/A
- Revenue Growth
- DMF N/A
- PROK N/A
- 52 Week Low
- DMF $5.37
- PROK $0.68
- 52 Week High
- DMF $6.79
- PROK $4.44
- Technical
- Relative Strength Index (RSI)
- DMF 52.49
- PROK 23.62
- Support Level
- DMF $7.13
- PROK $0.87
- Resistance Level
- DMF $7.29
- PROK $1.00
- Average True Range (ATR)
- DMF 0.07
- PROK 0.10
- MACD
- DMF -0.01
- PROK -0.00
- Stochastic Oscillator
- DMF 48.00
- PROK 7.60
About DMF BNY Mellon Municipal Income Inc.
BNY Mellon Municipal Income, Inc. is a non-diversified closed-end management investment company. Its investment objective is to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital. The fund invests in municipal obligations that are rated investment grade and have maturities of less than one year. The company targets to invest in the sector such as education, pre-refunded muni, utility, transportation, healthcare, special tax, state/territory general obligations, industry revenue, and pollution control.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.